Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.
May 08, 2024
Share
Plus Therapeutics, Inc. (NasdaqCM:PSTV) acquired CNSide, a leptomeningeal metastases diagnostic platform on May 9, 2024.
Plus Therapeutics, Inc. (NasdaqCM:PSTV) completed the acquisition of CNSide, a leptomeningeal metastases diagnostic platform on May 9, 2024.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
PLUS THERAPEUTICS, INC. 
